8-K current report · filed Nov 10, 2026

Liquidia Corp (LQDA) 8-K Current Report: November 10, 2026

Item 2.02Item 8.01Item EX-99.1Item EX-99.2LQDA overview

Short answer

Liquidia Corp (LQDA) filed an 8-K current report with the SEC on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Liquidia announced third-quarter 2026 financial results for the period ended September 30, 2026.

Liquidia Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Liquidia announced third-quarter 2026 financial results for the period ended September 30, 2026
  • Corporate update accompanies the results, with substantive details in Exhibit 99.1

Item 8.01 · Other Events

  • Updated corporate presentation signals refreshed messaging for healthcare conferences, analysts, and investors
  • Exhibit 99.2 contains the substantive investor-facing information and may affect market expectations

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 YUTREPIA sales reached $222.7 million, up 31% sequentially and sharply strengthening the commercial growth profile
  • Global settlement resolved six United Therapeutics lawsuits, preserving YUTREPIA access but requiring $380.7 million in payments during 2026 and 2027
  • PH-ILD label removal and halted promotion narrow YUTREPIA’s addressable market, creating potential revenue pressure despite uninterrupted patient treatment
  • Net loss $236.3 million included a $389.7 million litigation charge, while adjusted EBITDA reached $140.5 million for the fifth consecutive quarter
  • Cash rose to $396.1 million before settlement payments, supporting obligations but leaving total liabilities at $708.4 million versus $682.9 million of assets

Item EX-99.2 · Exhibit EX-99.2

  • Q3 2026 net product sales $222.7M, up 31% sequentially, marking the fifth consecutive quarterly growth period
  • YUTREPIA demand broadened to 1,300 prescribers, with over 60% generating at least two referrals
  • Adjusted EBITDA $140.5M, up 46% sequentially, indicating substantial operating leverage from commercial scale
  • GAAP net loss $236.3M, driven by a $389.7M United Therapeutics litigation-settlement charge
  • Settlement supports continued YUTREPIA commercialization in PAH, while PH-ILD promotion and sales face label-related uncertainty

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Liquidia Corp 8-K filings

Get the next LQDA 8-K as it lands

Follow LQDA for push alerts, or ask the research agent what this filing means.